| Targeting transcription factors for cancer treatment M Lambert, S Jambon, S Depauw, MH David-Cordonnier Molecules 23 (6), 1479, 2018 | 377 | 2018 |
| Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma B Moghimi, S Muthugounder, S Jambon, R Tibbetts, L Hung, H Bassiri, ... Nature communications 12 (1), 511, 2021 | 132 | 2021 |
| Direct and indirect targeting of HOXA9 transcription factor in acute myeloid leukemia M Lambert, M Alioui, S Jambon, S Depauw, IV Seuningen, ... Cancers 11 (6), 837, 2019 | 57 | 2019 |
| Novel amidino substituted benzimidazole and benzothiazole benzo [b] thieno-2-carboxamides exert strong antiproliferative and DNA binding properties M Cindrić, S Jambon, A Harej, S Depauw, MH David-Cordonnier, ... European journal of medicinal chemistry 136, 468-479, 2017 | 56 | 2017 |
| Heterocyclic diamidine DNA ligands as HOXA9 transcription factor inhibitors: Design, molecular evaluation, and cellular consequences in a HOXA9-dependant leukemia cell model S Depauw, M Lambert, S Jambon, A Paul, P Peixoto, R Nhili, L Marongiu, ... Journal of medicinal chemistry 62 (3), 1306-1329, 2019 | 38 | 2019 |
| Synthesis, antitumor activity and DNA binding features of benzothiazolyl and benzimidazolyl substituted isoindolines I Sović, S Jambon, SK Pavelić, E Markova-Car, N Ilić, S Depauw, ... Bioorganic & medicinal chemistry 26 (8), 1950-1960, 2018 | 20 | 2018 |
| Synthesis, antitumor activity and DNA binding features of benzothiazolyl and benzimidazolyl substituted isoindolines I Sovic, S Jambon, SK Pavelic, E Markova-Car, N Ilic, S Depauw, ... Bioorganic & Medicinal Chemistry 26 (8), 1950-1960, 2018 | 12 | 2018 |
| Induction of AML cell differentiation using HOXA9/DNA binding inhibitors as a potential therapeutic option for HOXA9‐dependent AML M Lambert, S Jambon, MA Bouhlel, S Depauw, J Vrevin, S Blanck, ... HemaSphere 8 (5), e77, 2024 | 5 | 2024 |
| The role of integrin beta-1 in the chemoresistance of acute myeloid leukemia H Ogana, S Hurwitz, Z Wan, HN Kim, S Jambon, H Abdel-Azim, M Huang, ... Blood 140 (Supplement 1), 8799-8800, 2022 | 2 | 2022 |
| HOXA9 transcription factor as a target in acute myeloid leukemia: Transcription, cellular and in vivo consequences of its invalidation M Lambert, S Jambon, S Depauw, MA Bouhlel, M Figeac, ... European Journal of Cancer 1 (69), S23, 2016 | 1 | 2016 |
| CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells S Jambon, J Sun, S Barman, S Muthugounder, XR Bito, A Shadfar, ... Blood Cancer Discovery 6 (1), 55-72, 2025 | | 2025 |
| P-CD19CD20-ALLO1: Potent Fully Allogeneic CAR-T Therapy Targeting CD19 and CD20 with Superior Efficacy over Single-Target Products S Jambon, J Ruiz, A Garcia-Maldonado, M Chen, D Mendoza, G Arauz, ... Blood 144 (Supplement 1), 4805-4805, 2024 | | 2024 |
| Inhibition of the Leukemogenic Transcription Factor HOXA9: Validation in a Murine Leukemic Cell Model. S Depauw, M Lambert, S Jambon, A Paul, P Peixoto, R Nhili, L Marongiu, ... Leukemia2019-The European Congress on Leukemias, between Cutting Edge and …, 2019 | | 2019 |
| Inhibition du facteur de transcription leucémogène HOXA9: validation dans un modèle leucémique murin. S Depauw, M Lambert, S Jambon, A Paul, DW Boykin, WD Wilson, ... 39e Congrès de la Société Française d’Hématologie, 2019 | | 2019 |
| Inhibitors of HOXA9 leukemogenic transcription factor are efficient on human AML cell models but not on normal human bone marrow CD34+ hematopoietic cells. M Lambert, S Depauw, S Jambon, R Nhili, M Bellart, L Lutchmee, ... 24th Congress of the European Hematology Association (EHA), 2019 | | 2019 |
| Identification of the transcription factor HOXA9 as a therapeutic target in renal cell carcinoma and targeting with DNA ligands S Jambon < bound method Organization. get_name_with_acronym of< Organization: TEL …, 2018 | | 2018 |
| Identification du facteur de transcription HOXA9 comme cible thérapeutique dans le carcinome à cellules rénales et ciblage par des ligands de l’ADN S Jambon Université de Lille (2018-2021), 2018 | | 2018 |
| Hoxa9 transcription factor: a potential novel therapeutic target in renal cell carcinoma M Lambert, S Jambon, M Figeac, M Perrais, M David-Cordonnier 25th Biennial Congress of the European Association for Cancer Research, 2018 | | 2018 |
| PO-133 Hoxa9 transcription factor: a potential novel therapeutic target in renal cell carcinoma (RCC) S Jambon, M Lambert, S Depauw, M Figeac, M Perrais, ... ESMO Open 3, A73, 2018 | | 2018 |
| HOXA9 transcription factor: a potential novel therapeutic target in renal cell carcinoma (RCC). S Jambon, M Lambert, S Depauw, M Figeac, M Perrais, ... 25th Biennial Congress of the European Association for Cancer Research (EACR …, 2018 | | 2018 |